Polypyrrole nanoparticles combine drug delivery and heating in prostate cancer cells
Published in Drugs development & discovery, Journals, Nanomedicine.
Published October 26, 2026.
Fatemeh Imani and colleagues report a nanoparticle platform combining doxorubicin delivery with light-generated heating in prostate cancer cell cultures. Their study appeared October 26 in Scientific Reports as an early, accepted article that remains subject to editorial changes.
The team investigated how oxidation defects in polypyrrole influence near-infrared absorption: more defects were associated with weaker absorption. They then attached hyaluronic acid, intended to target CD44, and loaded the particles with doxorubicin.
Tests used three prostate cancer cell lines: PC-3, DU145 and LNCaP. Drug-only effects depended on particle size in CD44-positive cells, whereas photothermal cell killing occurred independently of CD44 expression. Combining chemotherapy and photothermal treatment reduced measured viability below 15% in all three lines under the tested conditions.
These findings concern laboratory cancer cells, not patient outcomes. They do not establish selective delivery throughout a living body, acceptable tissue heating, long-term safety or clinical effectiveness. Further preclinical validation would be needed before interpreting this as a treatment option.
Source: Imani et al., Scientific Reports, October 26, 2026. DOI: 10.1038/s41598-026-77770-5.